A bispecific antibody–drug conjugate (ADC) composed of fully human common light-chain antibodies that simultaneously target c-MET (HGF receptor) and EGFR on tumor cells. Dual binding promotes internalization and intracellular release of a cytotoxic payload, killing c-MET/EGFR–expressing cells and concurrently inhibiting MET and EGFR signaling. Administered intravenously as monotherapy every 3 weeks in Phase 1 dose escalation/expansion.